Literature DB >> 1559334

Interrelationship of serum levonorgestrel and sex hormone-binding globulin levels following vaginal and oral administration of combined steroid contraceptive tablets.

K A Abdalla1, M M Shabaan, F Z Stanczyk.   

Abstract

Ten women were treated daily with a standard dose contraceptive tablet containing 0.25 mg levonorgestrel (LNG) in combination with 0.05 mg ethinylestradiol. Five women used the tablet vaginally, while the other five used it orally. Blood samples were taken at frequent intervals on the first day of treatment and after 1 and 2 hours on treatment days 7 and 14. Serum LNG levels were measured by radioimmunoassay, and sex hormone-binding globulin (SHBG) was quantitated by charcoal assay. On day 1, peak concentrations of LNG (5.1 ng/ml) occurred within 2 hours in the oral group, whereas in the vaginal group a peak of 2.2 ng/ml was reached after 4 hours. After 24 hours, mean serum concentrations of LNG were 1.1 and 0.69 ng/ml in the oral and vaginal groups, respectively. In both groups, mean LNG concentrations increased dramatically on days 7 and 14 compared to day 1. There was no significant difference between the two groups in LNG concentrations, except after 2 hours on day 1. SHBG levels were increased after one day of treatment. By day 14 of treatment, there was a 3.5- to 4.5-fold rise in SHBG levels from pretreatment values in both groups. However, there was no significant difference in SHBG levels between the two groups throughout the study. A high correlation was found between serum levels of SHBG and LNG in both the vaginal and oral groups. The results suggest that the increase in serum LNG levels in women receiving combined contraceptive tablets either vaginally or orally is due to increased levels of SHBG. Also, the measured concentrations of LNG in the vaginal group are consistent with the previously reported clinical contraceptive efficacy of combined contraceptive tablets administered vaginally.

Entities:  

Keywords:  Africa; Arab Countries; Biology; Contraception; Contraceptive Agents, Estrogen--administraction and dosage; Contraceptive Agents, Female--administraction and dosage; Contraceptive Agents, Female--analysis; Contraceptive Agents, Progestin--administraction and dosage; Contraceptive Agents, Progestin--analysis; Contraceptive Agents--administraction and dosage; Contraceptive Agents--analysis; Contraceptive Effectiveness; Contraceptive Methods--administraction and dosage; Developing Countries; Egypt; Ethinyl Estradiol--administraction and dosage; Examinations And Diagnoses; Family Planning; Hematologic Tests; Laboratory Examinations And Diagnoses; Laboratory Procedures; Levonorgestrel--administraction and dosage; Levonorgestrel--analysis; Mediterranean Countries; Metabolic Effects; Northern Africa; Oral Contraceptives, Combined--administraction and dosage; Oral Contraceptives--administraction and dosage; Physiology; Steroid Metabolic Effects

Mesh:

Substances:

Year:  1992        PMID: 1559334     DOI: 10.1016/0010-7824(92)90045-u

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  3 in total

Review 1.  Levonorgestrel. Clinical pharmacokinetics.

Authors:  K Fotherby
Journal:  Clin Pharmacokinet       Date:  1995-03       Impact factor: 6.447

2.  The Effect of Gene Variants on Levonorgestrel Pharmacokinetics When Combined With Antiretroviral Therapy Containing Efavirenz or Nevirapine.

Authors:  M Neary; M Lamorde; A Olagunju; K M Darin; C Merry; P Byakika-Kibwika; D J Back; M Siccardi; A Owen; K K Scarsi
Journal:  Clin Pharmacol Ther       Date:  2017-05-30       Impact factor: 6.875

Review 3.  Pharmacokinetics, metabolism and serum concentrations of progestins used in contraception.

Authors:  Alexis J Bick; Renate Louw-du Toit; Salndave B Skosana; Donita Africander; Janet P Hapgood
Journal:  Pharmacol Ther       Date:  2020-12-13       Impact factor: 13.400

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.